Hello! I've just written an article about milrinone for this website. In it, I delve into milrinone's pharmacological properties and clinical trials and explore its classification as a phosphodiesterase inhibitor, specifically targeting phosphodiesterase type 3 (PDE3). This mechanism of action leads to increased intracellular levels of cyclic AMP (cAMP), which in turn enhances myocardial contractility and promotes vasodilation.
Read here: https://www.cvdapp.com/milrinone-drug
Commenti